West Pharmaceutical draws $200M term loan in $950M refinancing
What's the deal? West Pharmaceutical ServicesDealroom has a profile for this one. Try Dealroom → has drawn a $200 million term loan as part of a new $950 million unsecured credit facility, with Bank of America, N.A. serving as administrative agent. The package, finalised October 26, 2026, pairs the term loan with a $750 million revolving credit line.
Why now? The facility replaces West's 2019 credit agreement, terminated the same day after the company repaid $130 million in outstanding principal. West confirmed it paid no early termination fees.
What's the endgame? West, based in Exton, Pennsylvania, supplies injectable drug containment, delivery, and contract-manufacturing services. It intends to use proceeds for working capital, capital expenditures, general corporate purposes, permitted acquisitions, stock repurchases, and debt repayment.
The five-year agreement carries a net leverage ratio cap of 3.50 to 1.0, rising to 4.00 to 1.0 during material acquisition periods. Quarterly term-loan amortisation of $1.25 million to $2.5 million begins March 31, 2028, with the balance due at maturity.
The refinancing follows strong momentum: West reported 13.8% second-quarter sales growth and raised its 2026 organic-growth outlook to 10%–11%. The company continues to invest in capacity for injectable and high-volume therapies, including GLP-1 drugs.
The signal: The move is a liquidity and flexibility play, not a strategy shift — a larger, longer facility that gives West room for acquisitions and capital spending as demand for injectable drug delivery grows.
Read more: kalkinemedia.com
Image credit: Generated with Gemini
